H.
Lundbeck A/S's deal with Otsuka
Pharmaceutical Co. Ltd. for two late-stage programs is designed to take
the Danish pharma beyond replacing patent-related revenue losses, giving it
products to establish a foothold in the U.S. psychiatry market in advance of
launching its own depression drug.
In November, the companies
partnered to co-develop and co-commercialize two late-stage programs from
Otsuka and up to three programs from Lundbeck. The deal includes Otsuka's
once-monthly depot formulation of aripiprazole for maintenance treatment of
schizophrenia, which FDA accepted for review on Nov. 22. The PDUFA date is
undisclosed.